Corticotropin-releasing factor (CRF) and urocortins have traditionally been proposed to promote stress and stress recovery, respectively. However, recent findings suggest that this view is overly ...

NBIP-01435 is an investigational long-acting corticotropin-releasing factor type 1 receptor (CRF 1) antagonist. CRF 1 antagonism has been shown to improve androgen control and allow for lower, ...

Corticotropin-releasing factor (CRF) is an early signal of the stress response and is also an important neuromodulator of memory consolidation, anxiety, locomotor activity and food intake. In ...

Roberto et al. Corticotropin Releasing Factor-Induced Amygdala Gamma-Aminobutyric Acid Release Plays a Key Role in Alcohol Dependence. Biological Psychiatry , 2010; DOI: 10.1016/j.biopsych.2009.11.007 ...

Increased allergic reactions may be tied to the corticotropin-releasing stress hormone ... (SCF) expression, a growth factor of mast cells, in human nasal mucosa- the skin of the nasal cavity.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced top-line efficacy and safety results from a Phase II clinical trial utilizing Corticotropin Releasing Factor (CRF1) receptor antagonist ...

To test this idea, they suppressed the activity of the mPFC in some of the mice–and specifically, a group of neurons that produce a hormone called corticotropin-releasing factor (CRF), which is ...

A new study in Biological Psychiatry reports that overexpression of corticotropin-releasing factor (CRF), a stress-related gene, increases anxious temperament in monkeys. According to Ned Kalin ...

Valentino's research focuses on corticotropin-releasing factor (CRF), a hormone released in the brain in responses to stress, in both humans and rats. CRF is a neurotransmitter, meaning it helps ...

Role of corticotropin-releasing factor on bladder function in rats with psychological stress. Share this article Medically reviewed by Madeline Knott, MD — Written by Rachel Ann Tee-Melegrito on ...

Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 trials involving patients with CAH. Methods.